Plasma asymmetric dimethylarginine in active rheumatoid arthritis: Links with oxidative stress and inflammation

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 6, 2012, Pages 270-276

  Kwaśny Krochin, Beata ^a   Głuszko, Piotr ^b   Undas, Anetta ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

Asymmetric dimethylarginine; Endothelium; Inflammation; Isoprostanes; Rheumatoid arthritis

Indexed keywords

6 N,N' DIMETHYLARGININE; 8 ISO PROSTAGLANDIN F2 ALPHA; ARGININE; C REACTIVE PROTEIN; CHLOROQUINE; CREATININE; CYCLOSPORIN; ETANERCEPT; FIBRINOGEN; LEFLUNOMIDE; METHOTREXATE; N(G),N(G) DIMETHYLARGININE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROSTAGLANDIN F2 ALPHA; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY FUNCTION; MALE; MONOTHERAPY; OXIDATIVE STRESS; PROSTAGLANDIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; THROMBOCYTE COUNT;

EID: 84863735203     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1277     Document Type: Article

References (33)

1. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005; 52: 722-732. (Pubitemid 40365093)
2. Gonzales MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med. 2003; 115 Suppl 8A: 99S-106S.
3. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford). 2009; 48: 11-22.
4. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J. 2009; 73: 411-418.
5. Böger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med. 2003; 41: 1467-1472. (Pubitemid 37493562)
6. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6: 508-519. (Pubitemid 43980523)
7. Suwaidi J, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101: 948-954. (Pubitemid 30131694)
8. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005; 97: e53-59.
9. Surdacki A, Martens-Lobenhoffer J, Wloch A, et al. Plasma asymmetric dimethylarginine is related to anticitrullinated protein antibodies in rheumatoid arthritis of short duration. Metabolism. 2009; 58: 316-318.
10. Surdacki A, Martens-Lobenhoffer J, Wloch A, et al. Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2007; 56: 809-819. (Pubitemid 46399428)
11. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999; 99: 1141-1146. (Pubitemid 29120084)
12. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 2002; 46: 862-873. (Pubitemid 34303796)
13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 315-324. (Pubitemid 18091653)
14. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38: 44-48.
15. Bruce B, Fries JF. The Standford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003; 1: 20.
16. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem. 2002; 303: 131-137. (Pubitemid 34407576)
17. Bergholm R, Leirisalo-Repo M, Vehkavaara S, et al. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 2002; 22: 1637-1641.
18. Hänsel S, Lässig G, Pistrosch F, Passauer J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis. 2003; 170: 177-180. (Pubitemid 37083577)
19. Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 2002; 106: 1439-1441.
20. Halliwell B. Oxygen radicals, nitric oxide and human inflammatory joint disease. Ann Rheum Dis. 1995; 54: 505-510.
21. Ames PR, Alves J, Murat I, et al. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology (Oxford). 1999; 38: 529-534. (Pubitemid 29504838)
22. Basu S, Whiteman M, Mattey DL, Halliwell B. Raised levels of F(2)- isoprostanes and prostaglandin F(2alpha) in different rheumatic diseases. Ann Rheum Dis. 2001; 60: 627-631. (Pubitemid 32493991)
23. Kageyama Y, Takahashi M, Ichikawa T, et al. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2008; 26: 73-80. (Pubitemid 351385258)
24. Fleck C, Janz A, Schweitzer F, et al. Serum concentration of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl. 2001; 78: S14-S18. (Pubitemid 32144063)
25. Ridker PM, Hennekens CH, Buning JE, Rifai N. C-reactive protein and the other markers of inflammation in the prediction of cardiovascular diseases in women. N Engl J Med. 2000; 342: 836-843. (Pubitemid 30165206)
26. Gussekloo J, Schaap MC, Frölich M, et al. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol. 2000; 20: 1047-1051. (Pubitemid 30207580)
27. Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 2005; 52: 2293-2299. (Pubitemid 41117412)
28. Hannawi S, Haluska B, Marwick TH, Thomas R. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther. 2007; 9: R116.
29. Sari I, Kebapcilar L, Alacacioglu A, et al. Increased levels of asymmetric dimethylarginine (ADMA) reflecting endothelial dysfunction in ankylosing spondylitis. Ann Rheum Dis. 2009; 68: 1363-1368.
30. Turiel M, Tomasoni L, Sitia S, et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc. Therap. 2010; 28: e53-64
31. Lotz M. Neuropeptides, free radicals and nitric oxide. In: Hochberg MC, Silman AJ, Smolen JS, eds. Rheumathology. 3rd edition. Maryland Heights, Mo: Mosby; 2003: 135-146.
32. Hegde LG, Srivastava P, Kumari R, Dikshit M. Alterations in the vasore-activity of hypertensive rat aortic rings: role of nitric oxide and superoxide radicals. Clin Exp Hypertens. 1998; 20: 885-901. (Pubitemid 28487521)
33. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem. 2003; 278: 22 546-22 554.